This study will test the feasibility, safety, and evidence for the efficacy of psilocybin administration in participants with obsessive-compulsive disorder (OCD).
Status: Not yet recruiting
Start date: 2022-09-30
Phase I
Open
30 participants
Interventional
This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin's therapeutic effects on OCD.
Status: Not yet recruiting
Start date: 2022-11-01
Phase I
Blinded
30 participants
Interventional
This study aims to investigate the effects of oral psilocybin on OCD symptomatology and provide the first evidence of the neural mechanism that may mediate psilocybin's purported therapeutic effects on OCD.
Status: Recruiting
Start date: 2018-11-13
Phase I
Blinded
30 participants
Interventional
In this pilot study, 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin. Follow-up visits to monitor safety and clinical outcome will be conducted over a 3 month period.
Status: Active, not recruiting
Start date: 2021-2-26
Phase II
Open
12 participants
Interventional
The purpose of the current study is to explore new alternative options for the treatment of OCD that can widely and continuously benefit patients. Specifically, the aim of this study is to investigate the feasibility, safety and efficacy of psilocybin-assisted psychotherapy for treatment of severe OCD.
Status: Not yet recruiting
Start date: 2021-1-12
Phase I
Open
15 participants
Interventional
This retrospective analysis aims to look at past data in order to further develop our understanding of ketamine in the use of psychiatry.
Status: Enrolling by invitation
Start date: 2019-12-3
Open
260 participants
Observational
This study will evaluate whether psilocybin, a hallucinogenic drug, improves symptoms of obsessive compulsive disorder (OCD), whether it is safely tolerated as treatment of OCD, and will investigate the mechanisms by which it works.
Status: Recruiting
Start date: 2019-1-2
Phase I
Blinded
15 participants
Interventional
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
